Understand the evidence
Assess the strength and limits of clinical and mechanistic data, alongside the competitive and development context.
Selective clinical asset origination · Active field BD
From clinical evidence to strategic engagement.
TSCIP evaluates scientifically credible clinical-stage oncology assets, identifies relevant pharmaceutical counterparties, and helps advance the business development process when an opportunity warrants direct engagement.
TSCIP stands for Tumor State Combination Intelligence Platform. Independent intelligence and experience-driven transaction support.
From asset thesis to counterparty action
01
Scientific credibility
Evaluate the human evidence and mechanistic rationale.
02
Strategic relevance
Determine where an asset may fit—or compete.
03
Focused engagement
Support qualified buyer conversations where appropriate.
04
Transaction readiness
Clarify the evidence, development and rights path forward.
Not another open asset marketplace.
Selective coverageBuyer-centric evaluationActive BD when needed
Why TSCIP
Good science does not always become a transaction.
Promising assets can encounter capital constraints, portfolio reprioritization, uncertain partnering pathways or evidence requirements that differ among buyers. TSCIP concentrates on the decisions that could make a credible opportunity actionable.
Think like the counterparty
Examine relevance to potential pharmaceutical partners, their strategic alternatives and likely decision requirements.
Move beyond analysis
Translate findings into focused development choices, credible outreach and practical transaction conversations.
How TSCIP works
From independent screening to a credible engagement path.
Our approach is selective and transaction-focused. TSCIP Covered Assets are independently chosen for their prospective strategic relevance; paying for intelligence does not guarantee buyer-facing coverage.
Selectivity first
Identify assets with meaningful scientific support and a plausible strategic rationale.
Decision-grade context
Bring together asset evidence, competitors, substitutes and development needs.
Qualified relevance
Consider appropriate pharmaceutical buyers and potential transaction pathways.
Practical BD
Where engaged, support outreach, discussions and the next evidence or rights decisions.
Who we serve
Different stakeholders. A shared need for credible decisions.
TSCIP bridges clinical asset owners, pharmaceutical counterparties and providers of strategic capital—while keeping each party's incentives and information boundaries distinct.
Clinical asset owners
Improve asset and partnering readiness, understand likely counterparty barriers, and draw on targeted BD execution when needed.
For asset owners →Pharma & strategic buyers
Review selected clinical asset opportunities with relevant evidence and clear access permissions. There are no fees to pharmaceutical buyers for accessing or evaluating TSCIP opportunities.
For pharma buyers →Strategic capital
Explore scientifically grounded assets where a focused development tranche, collaboration, or asset-rights structure may create value. Commercial terms are evaluated by opportunity.
For capital providers →For asset owners
Better partnering readiness, without replacing your BD team.
We complement the owner's business development efforts with independent assessment, evolving market context and direct transaction support when an engagement calls for it.
- → Maintained Asset Intelligence
- → Partnering Intelligence and counterparty relevance
- → Targeted field BD and transaction coordination
A tailored level of involvement
Intelligence when you need clarity. Field execution when you need momentum.
TSCIP engagements can focus on maintaining external asset intelligence, sharpening the partnering case, or supporting specific counterparty interactions. The work is aligned with the owner's development priorities and permissions.
Independent analysisTransaction focusOwner collaborationFor pharma & strategic buyers
Vetted opportunities, without another sourcing fee.
Pharmaceutical business development, search-and-evaluation and external innovation teams can review TSCIP-selected opportunities supported by independently grounded clinical and strategic context.
No fees are charged to pharma buyers for access to or evaluation of TSCIP-originated opportunities. Material nonpublic information is disclosed only through appropriate authorized channels.
For buyer teams
Relevant assets. Clearer decisions. Controlled access.
TSCIP focuses on scientifically credible asset opportunities and the transaction-specific questions that shape buyer interest, rather than open listings or indiscriminate deal flow.
Curated opportunitiesEvidence-groundedPermissioned reviewFor strategic capital
Capital opportunities grounded in the next evidence decision.
Some promising clinical assets are constrained by financing, changes in strategic priority, or the cost of the next study. TSCIP explores where targeted external capital or rights-based structures may enable a specific development path.
Structures and commercial arrangements are considered individually. TSCIP does not present a one-size-fits-all capital product.
Potential paths
Match the funding structure to the evidence milestone.
A discussion may involve partner-funded evidence generation, asset or regional rights, development collaboration, or other non-securities structures suited to the opportunity.
TSCIP does not represent that any asset has secured financing or a transaction.
Beyond the dashboard
We field BD where it matters to advance transactions.
Intelligence is useful when it changes a decision. For selected engagements, TSCIP supports direct outreach, counterparty discussions, assessment of feedback and the work required to progress a prospective licensing, collaboration or asset-rights transaction.
- ✓ Counterparty prioritization and qualified introductions
- ✓ Evidence and development-path discussions
- ✓ Transaction planning and negotiation support
An engaged transaction pathway
Assessment is the beginning—not the end.
01 · Credible thesis02 · Relevant parties03 · Targeted dialogue04 · Actionable next steps
TSCIP complements, rather than replaces, the asset owner's existing BD function.
Separate research platform
Introducing TSRIP.
TSRIP — Tumor State Research Intelligence Platform is a separate research initiative in development. It explores tumor-state-informed combination hypotheses and possible co-formulation or delivery approaches, translating them into ranked, experimentally testable options.
TSRIP proposes research directions for qualified laboratories to evaluate; it does not claim that candidate formulations or combinations have been manufactured or validated.
Research concept → experimental plan
From scientific rationale to the next test.
Investigate combination hypotheses, compare plausible delivery architectures and identify the experimental gates needed to establish feasibility.
Tumor statesCombination conceptsFormulation feasibilityStart a conversation
Have a clinical asset or strategic interest to discuss?
We welcome focused conversations with clinical asset owners, pharma business development teams and strategic partners.